IDEXX LABORATORIES INC (IDXX) Stock Fundamental Analysis
USA - NASDAQ:IDXX - US45168D1046 - Common Stock
634.36 USD
-13.04 (-2.01%)
634.36 USD
0 (0%)
IDXX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IDXX a very profitable company, without any liquidiy or solvency issues. IDXX is not valued too expensively and it also shows a decent growth rate. With these ratings, IDXX could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
In the past year IDXX was profitable.
In the past year IDXX had a positive cash flow from operations.
Each year in the past 5 years IDXX has been profitable.
Each year in the past 5 years IDXX had a positive operating cash flow.
1.2 Ratios
IDXX has a better Return On Assets (29.59%) than 98.94% of its industry peers.
IDXX's Return On Equity of 67.56% is amongst the best of the industry. IDXX outperforms 99.47% of its industry peers.
Looking at the Return On Invested Capital, with a value of 37.30%, IDXX belongs to the top of the industry, outperforming 99.47% of the companies in the same industry.
IDXX had an Average Return On Invested Capital over the past 3 years of 35.08%. This is significantly above the industry average of 9.01%.
The last Return On Invested Capital (37.30%) for IDXX is above the 3 year average (35.08%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.59% | ||
| ROE | 67.56% | ||
| ROIC | 37.3% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
1.3 Margins
Looking at the Profit Margin, with a value of 24.41%, IDXX belongs to the top of the industry, outperforming 94.18% of the companies in the same industry.
IDXX's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 31.09%, IDXX belongs to the top of the industry, outperforming 97.88% of the companies in the same industry.
IDXX's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 61.54%, IDXX is in the better half of the industry, outperforming 62.96% of the companies in the same industry.
IDXX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.09% | ||
| PM (TTM) | 24.41% | ||
| GM | 61.54% |
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.55%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IDXX is creating value.
The number of shares outstanding for IDXX has been reduced compared to 1 year ago.
The number of shares outstanding for IDXX has been reduced compared to 5 years ago.
The debt/assets ratio for IDXX has been reduced compared to a year ago.
2.2 Solvency
IDXX has an Altman-Z score of 21.57. This indicates that IDXX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of IDXX (21.57) is better than 95.24% of its industry peers.
The Debt to FCF ratio of IDXX is 1.43, which is an excellent value as it means it would take IDXX, only 1.43 years of fcf income to pay off all of its debts.
IDXX's Debt to FCF ratio of 1.43 is amongst the best of the industry. IDXX outperforms 89.95% of its industry peers.
A Debt/Equity ratio of 0.71 indicates that IDXX is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.71, IDXX is not doing good in the industry: 70.37% of the companies in the same industry are doing better.
Even though the debt/equity ratio score it not favorable for IDXX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 1.43 | ||
| Altman-Z | 21.57 |
ROIC/WACC4.14
WACC9.02%
2.3 Liquidity
A Current Ratio of 1.11 indicates that IDXX should not have too much problems paying its short term obligations.
IDXX's Current ratio of 1.11 is on the low side compared to the rest of the industry. IDXX is outperformed by 85.71% of its industry peers.
IDXX has a Quick Ratio of 1.11. This is a bad value and indicates that IDXX is not financially healthy enough and could expect problems in meeting its short term obligations.
IDXX has a Quick ratio of 0.79. This is amonst the worse of the industry: IDXX underperforms 84.66% of its industry peers.
The current and quick ratio evaluation for IDXX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.11 | ||
| Quick Ratio | 0.79 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 12.45% over the past year.
IDXX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.18% yearly.
IDXX shows a small growth in Revenue. In the last year, the Revenue has grown by 6.68%.
Measured over the past years, IDXX shows a quite strong growth in Revenue. The Revenue has been growing by 10.12% on average per year.
EPS 1Y (TTM)12.45%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%20.2%
Revenue 1Y (TTM)6.68%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%10.55%
3.2 Future
Based on estimates for the next years, IDXX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.68% on average per year.
The Revenue is expected to grow by 8.69% on average over the next years. This is quite good.
EPS Next Y14.37%
EPS Next 2Y13.27%
EPS Next 3Y13.08%
EPS Next 5Y11.68%
Revenue Next Year9.1%
Revenue Next 2Y8.66%
Revenue Next 3Y8.63%
Revenue Next 5Y8.69%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 52.82, which means the current valuation is very expensive for IDXX.
Compared to the rest of the industry, the Price/Earnings ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 68.25% of the companies listed in the same industry.
IDXX is valuated expensively when we compare the Price/Earnings ratio to 26.83, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 43.95, the valuation of IDXX can be described as expensive.
Based on the Price/Forward Earnings ratio, IDXX is valued a bit cheaper than 70.37% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.88, IDXX is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.82 | ||
| Fwd PE | 43.95 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IDXX is valued a bit cheaper than 69.84% of the companies in the same industry.
73.02% of the companies in the same industry are more expensive than IDXX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 65.54 | ||
| EV/EBITDA | 37.44 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IDXX may justify a higher PE ratio.
IDXX's earnings are expected to grow with 13.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.68
PEG (5Y)2.91
EPS Next 2Y13.27%
EPS Next 3Y13.08%
5. Dividend
5.1 Amount
IDXX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
634.36
-13.04 (-2.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners97.04%
Inst Owner Change-0.21%
Ins Owners0.2%
Ins Owner Change2.22%
Market Cap50.75B
Revenue(TTM)4.04B
Net Income(TTM)985.66M
Analysts79.05
Price Target694.47 (9.48%)
Short Float %2.24%
Short Ratio4.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.76%
Min EPS beat(2)1.72%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)4.73%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.6%
EPS beat(12)12
Avg EPS beat(12)4.41%
EPS beat(16)14
Avg EPS beat(16)3.9%
Revenue beat(2)1
Avg Revenue beat(2)-0.02%
Min Revenue beat(2)-1.92%
Max Revenue beat(2)1.88%
Revenue beat(4)2
Avg Revenue beat(4)-0.58%
Min Revenue beat(4)-2.33%
Max Revenue beat(4)1.88%
Revenue beat(8)2
Avg Revenue beat(8)-1.32%
Revenue beat(12)2
Avg Revenue beat(12)-1.2%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)0.43%
PT rev (3m)28.15%
EPS NQ rev (1m)0.16%
EPS NQ rev (3m)1.03%
EPS NY rev (1m)0.13%
EPS NY rev (3m)3.64%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)2.24%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)2.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 52.82 | ||
| Fwd PE | 43.95 | ||
| P/S | 12.57 | ||
| P/FCF | 65.54 | ||
| P/OCF | 56.03 | ||
| P/B | 34.79 | ||
| P/tB | 53.95 | ||
| EV/EBITDA | 37.44 |
EPS(TTM)12.01
EY1.89%
EPS(NY)14.44
Fwd EY2.28%
FCF(TTM)9.68
FCFY1.53%
OCF(TTM)11.32
OCFY1.78%
SpS50.47
BVpS18.24
TBVpS11.76
PEG (NY)3.68
PEG (5Y)2.91
Graham Number70.2
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.59% | ||
| ROE | 67.56% | ||
| ROCE | 59.57% | ||
| ROIC | 37.3% | ||
| ROICexc | 39.73% | ||
| ROICexgc | 50.01% | ||
| OM | 31.09% | ||
| PM (TTM) | 24.41% | ||
| GM | 61.54% | ||
| FCFM | 19.18% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
ROICexc(3y)39.8%
ROICexc(5y)41.54%
ROICexgc(3y)51.52%
ROICexgc(5y)54.69%
ROCE(3y)52.73%
ROCE(5y)50.92%
ROICexgc growth 3Y-5.99%
ROICexgc growth 5Y4.29%
ROICexc growth 3Y-3.86%
ROICexc growth 5Y4.07%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.55%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
F-Score7
Asset Turnover1.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 1.43 | ||
| Debt/EBITDA | 0.74 | ||
| Cap/Depr | 95.5% | ||
| Cap/Sales | 3.26% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 65.03% | ||
| Profit Quality | 78.56% | ||
| Current Ratio | 1.11 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 21.57 |
F-Score7
WACC9.02%
ROIC/WACC4.14
Cap/Depr(3y)119.66%
Cap/Depr(5y)117.12%
Cap/Sales(3y)3.91%
Cap/Sales(5y)3.89%
Profit Quality(3y)79.31%
Profit Quality(5y)83.23%
High Growth Momentum
Growth
EPS 1Y (TTM)12.45%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%20.2%
EPS Next Y14.37%
EPS Next 2Y13.27%
EPS Next 3Y13.08%
EPS Next 5Y11.68%
Revenue 1Y (TTM)6.68%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%10.55%
Revenue Next Year9.1%
Revenue Next 2Y8.66%
Revenue Next 3Y8.63%
Revenue Next 5Y8.69%
EBIT growth 1Y15.86%
EBIT growth 3Y6.64%
EBIT growth 5Y15.38%
EBIT Next Year31.91%
EBIT Next 3Y16.8%
EBIT Next 5Y14.07%
FCF growth 1Y30.65%
FCF growth 3Y7.86%
FCF growth 5Y21.29%
OCF growth 1Y21.32%
OCF growth 3Y7.13%
OCF growth 5Y15.13%
IDEXX LABORATORIES INC / IDXX FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
Can you provide the valuation status for IDEXX LABORATORIES INC?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
Can you provide the profitability details for IDEXX LABORATORIES INC?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What is the valuation of IDEXX LABORATORIES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 52.82 and the Price/Book (PB) ratio is 34.79.
Can you provide the expected EPS growth for IDXX stock?
The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 14.37% in the next year.